Trial · NCT00928889
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) | Nateglinide 120 mg | -1.775 | Standard Deviation 1.3618 | mmol/L | |
| Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) | Acarbose 50 mg | -2.434 | Standard Deviation 1.4418 | mmol/L | |
| Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4) | Nateglinide 120 mg | -2.350 | Standard Deviation 1.8480 | mmol/L | |
| Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4) | Acarbose 50 mg | -3.129 | Standard Deviation 1.8151 | mmol/L | |
| Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4) | Nateglinide 120 mg | -217.628 | Standard Deviation 179.8929 | mmol*min/L | |
| Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4) | Acarbose 50 mg | -278.447 | Standard Deviation 171.2480 | mmol*min/L | |
| Change From Baseline in Total Cholesterol at the End of the Study (Week 4) | Nateglinide 120 mg | Fasting, N=74, 77 | 0.015 | Standard Deviation 0.742 | mmol/L |
| Change From Baseline in Total Cholesterol at the End of the Study (Week 4) | Acarbose 50 mg | Fasting, N=74, 77 | -0.149 | Standard Deviation 1.050 | mmol/L |
| Change From Baseline in Total Cholesterol at the End of the Study (Week 4) | Nateglinide 120 mg | 120 minutes, N=74, 76 | 0.010 | Standard Deviation 0.700 | mmol/L |
| Change From Baseline in Total Cholesterol at the End of the Study (Week 4) | Acarbose 50 mg | 120 minutes, N=74, 76 | -0.059 | Standard Deviation 0.682 | mmol/L |
| Change From Baseline in Triglycerides at the End of the Study (Week 4) | Nateglinide 120 mg | Fasting, N=74, 77 | -0.010 | Standard Deviation 0.737 | mmol/L |
| Change From Baseline in Triglycerides at the End of the Study (Week 4) | Acarbose 50 mg | Fasting, N=74, 77 | -0.418 | Standard Deviation 1.047 | mmol/L |
| Change From Baseline in Triglycerides at the End of the Study (Week 4) | Nateglinide 120 mg | 120 minutes, N=74, 76 | 0.026 | Standard Deviation 0.676 | mmol/L |
| Change From Baseline in Triglycerides at the End of the Study (Week 4) | Acarbose 50 mg | 120 minutes, N=74, 76 | -0.396 | Standard Deviation 0.891 | mmol/L |
| Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4) | Nateglinide 120 mg | Fasting, N=74, 77 | 0.036 | Standard Deviation 0.634 | mmol/L |
| Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4) | Acarbose 50 mg | Fasting, N=74, 77 | 0.036 | Standard Deviation 0.570 | mmol/L |
| Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4) | Nateglinide 120 mg | 120 minutes, N=74, 76 | -0.000 | Standard Deviation 0.604 | mmol/L |
| Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4) | Acarbose 50 mg | 120 minutes, N=74, 76 | 0.044 | Standard Deviation 0.589 | mmol/L |
| Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4) | Nateglinide 120 mg | Fasting, N=74, 77 | 0.020 | Standard Deviation 0.150 | mmol/L |
| Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4) | Acarbose 50 mg | Fasting, N=74, 77 | -0.039 | Standard Deviation 0.130 | mmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00928889/results